Medarex shareholders are not being compensated for the long-term risk that they had assumed.
Fully-Human antibody technology represents the "gold-standard" in the evolution cancer theraputics.

The Medarex Ulti-Mab system is a very robust antibody generating platform that is capable of generating a multitude of antibody candadates for clinical trial.

Medarex has more than 20 human antibody collaborations with some of the finest pharmaceutical companies in the world.

This company is capable of generating gold-mine profits for BMSquibb and its shareholders. Medarex shareholders should reject the terms of the tender offer.

While Medarex management and staff have performed well. Management negotiated a deal with BMSquib that does not fully reflect the real potential of this deal to BMSquibb.

Oh and lets not forget the Multimillon Dollar bonus that Howard Pien-current Medarex Chairman has negotiated for himself in the Medarex Fire Sale to BMSquibb

This is an outrage

I hope all Medarex shareholders reject the tender offer and force both companies to re-negotiate a better offer pprice for Medarex shareholders.